MEB fee rate change as of January 2019

The Medicines Evaluation Board (MEB) is increasing the fee rates for authorisation applications, authorisation changes and the annual fees of human medicinal products with 12.5% as of 2019. This is the first substantial increase since 2015.

The reasons for the increase are higher prices and salaries, IT investments and a number of new regular duties that will be incorporated in the rates. In the future, the MEB will index the rates on a yearly basis, to prevent big changes such as this year's.